San Jose, California (PRWEB) September 19, 2014
Stick to us on LinkedIn – Imaging agents, an integral element of the health-related imaging marketplace, are engineered to enhance the anatomic visualization of human organs. Effervescent technologies developments over the past three decades have expanded the application roles of imaging agents in health-related diagnostics. From barium and iodine primarily based agents utilised for over half a century to newer variants such as gold nanoparticles and radiopharmaceuticals, imaging agents have witnessed sea changes, revolutionizing in the process the field of health-related diagnosis. Growth in the market place is mainly driven by rise in imaging procedure volumes against the backdrop of an aging globe population and escalating incidence of chronic diseases. Also contributing to the development is expansion of imaging modalities in new clinical applications and advancements such as entire physique screening, therapeutic monitoring, and image guided therapeutic interventions. Improvement of targeted agents is anticipated to additional accelerate industry development.

Contrast media constitutes the largest segment with future development in this market forecast to come from robust demand for image guided surgical procedures, technological advancements in diagnostic imaging and increasing incidence of ailments such as cancer and cardiac failure. Within the contrast media segment, the mature X-ray contrast media technology is getting overshadowed by modern modalities such as MRI and Ultrasound, which are engineered to specially target certain tissues, such as, the liver and lymph nodes. Advancements in molecular diagnostics is also expected to drive the development of new contrast agents capable of detecting metabolic adjustments at the molecular level and assess functional modifications associated with heart, cancer, and neurological ailments. Fluorescence optical imaging, an evolving healthcare imaging modality, offers the prospective to complement current molecular imaging strategies. Development of advanced imaging agents is expected to facilitate higher precision diagnostics as well as promote the practice of customized medicine in the most cost-efficient manner.

Diagnostic radiopharmaceuticals are poised to register the fastest development more than the analysis period, buoyed by rising usage of Single Photon Emission Computed Tomography- Personal computer Tomography (SPECT-CT). Radiopharmaceuticals hold the prospective to offer you greater illness management to the elderly suffering from cognitive situations by delivering early illness identification and reduced cost of healthcare.

As stated by the new industry research report on Imaging Agents, the United States represents the biggest industry worldwide. Asia-Pacific is forecast to witness the quickest development, trailing a CAGR of ten.three% over the analysis period, driven by growing number of imaging procedures and penetration of imaging technologies. Developing awareness over the value of early diagnosis of ailments for enhanced management constitutes one more major element driving demand for medical imaging equipment and imaging agents.

Main players covered in the report include Bayer Healthcare Pharmaceuticals, Bracco Diagnostics Inc., Daiichi Sankyo Organization Restricted, Eisai Co. Ltd., Eli Lilly and Company, GE Healthcare, Guerbet Group, Lantheus Health-related Imaging Inc., and Mallinckrodt Pharmaceuticals amongst other people.

The study report titled “Imaging Agents: A Global Strategic Business Report” announced by Worldwide Market Analysts Inc., supplies a comprehensive assessment of market place trends, concerns, drivers, mergers, acquisitions and other strategic business activities of key firms worldwide. The report provides market estimates and projections for all major geographic markets like the United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India and Rest of Asia-Pacific), Middle East and Latin America (Brazil and Rest of Latin America). Product segments analyzed consist of Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals.

For much more information about this comprehensive market place study report, please check out – http://www.strategyr.com/Imaging_Agents_Marketplace_Report.asp

About Global Industry Analysts, Inc.
Worldwide Industry Analysts, Inc., (GIA) is a top publisher of off-the-shelf industry analysis. Founded in 1987, the organization at present employs more than 800 individuals worldwide. Annually, GIA publishes 1500+ full-scale study reports and analyzes 40,000+ industry and technology trends while monitoring much more than 126,000 Firms worldwide. Serving more than 9500 clients in 27 nations, GIA is recognized these days, as one particular of the world’s biggest and reputed marketplace analysis firms.

International Market Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977 
Email: press(at)StrategyR(dot)com
Internet Website: http://www.StrategyR.com/

###





Associated Higher Precision Components Press Releases